Stockscreener 앱 받기
5.19
2.08%
-0.11
시간 외 거래:
5.19
전일 마감가:
$5.30
열려 있는:
$5.35
하루 거래량:
308.30K
Relative Volume:
1.85
시가총액:
$196.98M
수익:
$239.40M
순이익/손실:
$104.44M
주가수익비율:
1.7534
EPS:
2.96
순현금흐름:
$-18.50M
1주 성능:
-10.52%
1개월 성능:
-27.51%
6개월 성능:
-59.89%
1년 성능:
-64.08%
1일 변동 폭
$5.05
$5.47
1주일 범위
$4.98
$6.04
52주 변동 폭
$4.98
$21.79
Entrada Therapeutics Inc Stock (TRDA) Company Profile
명칭
Entrada Therapeutics Inc
전화
857-305-1825
주소
ONE DESIGN CENTER PLACE, BOSTON
TRDA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
TRDA
Entrada Therapeutics Inc
|
5.19 | 225.82M | 239.40M | 104.44M | -18.50M | 2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Entrada Therapeutics Inc Stock (TRDA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-06 | 개시 | ROTH MKM | Buy |
| 2024-01-05 | 개시 | Oppenheimer | Outperform |
| 2023-04-03 | 개시 | H.C. Wainwright | Buy |
Entrada Therapeutics Inc 주식(TRDA)의 최신 뉴스
Is Entrada Therapeutics Inc. meeting your algorithmic filter criteriaWeekly Stock Picks with Trend Confidence - Newser
Entrada Therapeutics Inc. recovery potential after sell offFree Price Action Based Buy Opportunity List - Newser
Is Entrada Therapeutics Inc. stock bottoming outFree AI Screening for Swing Trade Picks - Newser
Applying chart zones and confluence areas to Entrada Therapeutics Inc.Portfolio Review Summary with Five-Year Outlook - Newser
What makes Entrada Therapeutics Inc. stock price move sharplyFree Fundamental Winners With Safe Entry Plan - Newser
Entrada Therapeutics' Revenue Estimates Cut by 57% Amid Weaker Q1 Results - AInvest
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - simplywall.st
Entrada Therapeutics, Inc. (NASDAQ:TRDA) Analysts Are Cutting Their Estimates: Here's What You Need To Know - uk.finance.yahoo.com
Measuring Entrada Therapeutics Inc.’s beta against major indicesMulti-Year Investment Performance Summary Report - Newser
Entrada Therapeutics (NASDAQ:TRDA) Downgraded to Sell Rating by Wall Street Zen - Defense World
Is Entrada Therapeutics Inc. stock reversal real or fakeFree Chart Alert System With Entry Targets - Newser
Live market analysis of Entrada Therapeutics Inc.Market Stability and Long-Term Growth Outlook - Newser
Sentiment analysis tools applied to Entrada Therapeutics Inc.Algorithmic Forecast for Swing Trading Picks - Newser
Real time breakdown of Entrada Therapeutics Inc. stock performancePredictive AI Engine for Smart Investing - Newser
Roth/MKM lowers Entrada Therapeutics stock price target to $17 from $21 - Investing.com Canada
Buy Rating for Entrada Therapeutics: Strong Pipeline and Financial Stability Amidst DMD Advancements - TipRanks
Entrada Therapeutics Second Quarter 2025 Earnings: Misses Expectations - Yahoo Finance
Entrada (TRDA) Q2 Revenue Drops 98% - AOL.com
Entrada Therapeutics 2025 Q2 Earnings Misses Targets with Net Loss Widens 178.3% - AInvest
Entrada Therapeutics Reports Q2 2025 Financial Results - TipRanks
Entrada Therapeutics Q2 Revenue Falls 98%, Losses Widen to $1.04 per Share - AInvest
Entrada (TRDA) Q2 Revenue Drops 98% - The Motley Fool
Entrada Therapeutics shares fall 1.01% after-hours after reporting a net loss of USD 43.1 million for Q2 2025. - AInvest
Entrada Therapeutics, Inc. (TRDA) Reports Q2 Loss, Lags Revenue Estimates - sharewise.com
Entrada Therapeutics Reports Q2 Loss, Misses Revenue Estimates, Shares Down 66.3% YTD - AInvest
Entrada Therapeutics August 2025 slides: advancing four clinical-stage programs - Investing.com Canada
Entrada Therapeutics earnings missed by $0.22, revenue fell short of estimates - Investing.com Canada
Entrada Therapeutics, Inc. SEC 10-Q Report - TradingView
Entrada Therapeutics Q2 collaboration revenue drops, net loss widens - MarketScreener
Entrada Therapeutics Reports Second Quarter 2025 Financial Results - Stock Titan
Promising Clinical Developments and Strategic Pipeline Expansion Support Buy Rating for Entrada Therapeutics - TipRanks
Can volume confirm reversal in Entrada Therapeutics Inc.Pattern Recognition Based Market Move Prediction - Newser
Pattern Scan Adds Entrada Therapeutics Inc. to WatchlistTrade Timing Strategy With Technical Data Explained - metal.it
Why Entrada Therapeutics Inc. stock attracts strong analyst attentionWatchlist Generator for Smart Money Signals - Newser
What drives Entrada Therapeutics Inc. stock priceDiscover market opportunities with real-time data - Jammu Links News
How strong is Entrada Therapeutics Inc. company’s balance sheetAchieve rapid portfolio appreciation today - Jammu Links News
What institutional investors are buying Entrada Therapeutics Inc. stockBreakout profit opportunities - Jammu Links News
Does Entrada Therapeutics Inc. stock perform well during market downturnsAccess powerful market insights for free - Jammu Links News
New Product Launches: Will They Boost Entrada Therapeutics Inc. Stock in 2025Free Conservative Long Term Growth Plans - Newser
What are Entrada Therapeutics Inc. company’s key revenue driversBuild wealth with proven stock investing tactics - Jammu Links News
How volatile is Entrada Therapeutics Inc. stock compared to the marketDiscover breakthrough investment opportunities - Jammu Links News
What analysts say about Entrada Therapeutics Inc. stockTransform your portfolio with high-yield stocks - Jammu Links News
What is the risk reward ratio of investing in Entrada Therapeutics Inc. stockAchieve rapid wealth accumulation with smart picks - Jammu Links News
Entrada Therapeutics Inc. Stock Analysis and ForecastTriple-digit returns - Jammu Links News
What are the latest earnings results for Entrada Therapeutics Inc.Free Wealth Management Insights - Jammu Links News
What catalysts could drive Entrada Therapeutics Inc. stock higher in 2025Build wealth with long-term growth strategies - Jammu Links News
Entrada Therapeutics Inc (TRDA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):